Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azithromycin ophthalmic - InSite Vision

Drug Profile

Azithromycin ophthalmic - InSite Vision

Alternative Names: AzaSite; Azasite; AzaSite Xtra; azithromycin ophthalmic 1%; azithromycin ophthalmic 2%; ISV-401; ISV-405; SJP-0118

Latest Information Update: 17 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InSite Vision
  • Developer Akorn; InSite Vision; Merck & Co; Senju Pharmaceutical; Tottori University Hospital
  • Class Antibacterials; Eye disorder therapies; Macrolides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Conjunctivitis

Highest Development Phases

  • Marketed Infectious conjunctivitis
  • No development reported Blepharitis; Ocular inflammation
  • Discontinued Infectious keratitis

Most Recent Events

  • 17 Jul 2019 Registered for Infectious conjunctivitis in Japan before July 2019 (Ophthalmic) (Senju pharmaceutical pipeline July 2019)
  • 13 Jun 2018 No development reported - Phase-III for Blepharitis in Japan (Instillation)
  • 13 Jun 2018 No development reported - Phase-III for Ocular inflammation in Japan (Instillation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top